Materials and methods This IRB-approved study compared 240 fluorine-18 fluorodeoxyglucose PET/CT consecutively dictated reports by two nuclear medicine subspecialists against the original outside institution reports. Subspecialist reviews documented whether malignant findings on the outside report were malignant and noted additional malignant findings not described on the outside report. The final diagnosis of malignancy or benignity was determined by pathology when available, otherwise by imaging follow-up.
Results A total of 22 findings (in 20 reports) called suspicious/malignant on the outside reports were deemed benign by subspecialist review. A final diagnosis was available for 20 of 22 findings by pathology (n = 3) or followup imaging (n = 17). The subspecialist review was accurate in 20 (100%) of 20 cases where a final diagnosis was available. The subspecialist review called 11 findings (in 11 reports) suspicious/malignant that were not described or deemed benign on the outside reports. Definitive diagnosis was available for 10 of 11 findings by pathology (n = 7) or follow-up imaging (n = 3). The second-opinion report was accurate in seven (70%) of 10 cases where a final diagnosis was available.
Conclusion
In 31 (13%) of 240 fluorine-18 fluorodeoxyglucose PET/CT examinations performed at an outside institution, subspecialist review resulted in at least one discordant opinion of malignancy. For 28 discrepant cases where a final diagnosis was available, the subspecialist review defined malignancy or benignity correctly in 25 (89%) of 28 cases. This provides evidence for the cost and effort invested in performing second-opinion reviews of PET/CT studies. Nucl Med Commun 38:306-311 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
In many specialty oncologic centers, radiology studies initially carried out and interpreted at an outside institution are subjected to a second review by in-house specialists. At our institution, the numbers of requests for in-house specialist reassessments of fluorine-18 fluorodeoxyglucose ( 18 F-FDG) PET/CT studies have been increasing rapidly. In 2010, 629 second opinion reviews of 18 F-FDG PET/CT scans were performed at our institution. By 2012, this number had increased to 1157, and in 2015, 2053 second opinion reviews of 18 F-FDG PET/CT scans were performed. Several studies have suggested that subspecialty reviews of body CT, neuroradiology, and mammography exams have varying levels of benefit, with discrepancy rates between the initial report and the specialist reassessment ranging between 1 and 19% [1] [2] [3] [4] [5] [6] [7] [8] . The value of subspecialist review of 18 F-FDG PET/CT scans is unknown. Determining the value of subspecialist review of outside institution PET/CT examinations is an important issue, particularly when considering the allocation of limited personnel and resources to perform these second-opinion reassessments, as well as whether a rationale exists for reimbursement of these reassessments, which add cost to patient care. In this study, we investigated whether nuclear medicine subspecialist reviews of outside institution PET/CT examinations resulted in more accurate reporting of malignant findings, with pathology or followup imaging as the gold standard.
Materials and methods
This study was carried out with institutional review board approval. The cohort consisted of 240 consecutive outside institution 18 F-FDG PET/CT examinations reassessed by two nuclear medicine subspecialists (G.A.U. and M.D.) between June and December 2010. Institutional policy requires an outside-hospital report to accompany examinations submitted for in-house reassessments; thus, outside-hospital reports were available on all studies. All studies were digitized into the institutional PACS and viewed as multiplanar 18 F-FDG PET, CT, and hybrid PET/CT images using GE PET/ CT software (GE Healthcare, Chicago, Illinois, USA) (AW suite).
Each exam was interpreted by a single specialist. The specialist reassessment included an evaluation of each organ system called suspicious or malignant on the outside report (e.g. right breast cancer with thoracic nodal, lung, and osseous metastases). For each organ system called suspicious or malignant on the outside report, the specialist documented whether they believed that the imaging findings were indeed malignant or benign. Specialist reassessment also documented additional organ systems believed to be suspicious for or containing malignancy that were either not mentioned on the outside report or were described as benign. All patients were then followed prospectively to document pathology and/ or follow-up imaging, which provided a final diagnosis of malignancy or benignity. Pathology was given precedence as the gold standard, but many findings described as benign on the subspecialist review were not histologically sampled, and in these cases, follow-up imaging was used. Follow-up was continued until December 2015.
Results
A total of 240 outside-hospital PET/CT examinationsone per patient -were reviewed for a second opinion, and the outside-hospital report was available for all 240 examinations. The most common primary malignancies of the patients in this study were breast cancer, lymphoma, and lung cancer. The characteristics for the 240 patients are reported in Table 1 .
Of the 240 18 F-FDG PET/CT examinations initially interpreted at an outside institution, 20 outside reports described suspicious/malignant findings that were called benign in the specialist review. This includes two examinations containing two findings called suspicious/ malignant on the outside report that were both deemed to be benign in the specialist review. Thus, a total of 22 findings in 20 examinations were called suspicious/ malignant in outside reports, but were deemed to be benign by specialist review (Table 2) . After prospective follow-up, a final diagnosis was available in 20 of these 22 findings by pathology (n = 3) or follow-up imaging (n = 17). In all 20 cases where a final diagnosis was available, the final diagnosis was benign. Thus, the specialist review accurately predicted benignity in all 20 (100%) of 20 cases. The most common findings called suspicious/malignant on outside reports but benign on second-opinion review were benign 18 F-FDG-avid mediastinal lymph nodes, 18 F-FDG-avid adnexal cysts in premenopausal women, and physiologic rectal sphincter 18 F-FDG avidity ( Table 1) Also within the cohort of 240 18 F-FDG PET/CT examinations were 11 examinations where additional suspicious/malignant findings were noted on the subspecialist second-opinion report, but were not included or were called benign on the initial outside-hospital report (Table 3) . After prospective follow-up, a final diagnosis 
Other = carcinoid (1), cholangiocarcinoma (1), desmoplastic small round cell tumor (1), hilar mass (1), increased carcinoembryonic antigen (1), neuroblastoma (1), synovial sarcoma (1). In all 20 cases with a diagnosis on follow-up, a benign etiology was confirmed. Outside-hospital PET-CT review Ulaner et al. 307
was available in 10 of the 11 cases by pathology (n = 7) or follow-up imaging (n = 3). In seven of 10 cases where a final diagnosis was available, the final diagnosis was malignant (70%). Thus, the specialist review accurately predicted additional malignancy in 70% of the cases where additional malignancy was described, but was incorrect in the remaining 30%. The most common finding called suspicious/malignant on the secondopinion report, but were not included or were called benign on the initial outside-hospital report were lung nodules with absent or low 18 F-FDG avidity. An example of a finding called suspicious/malignant on the secondopinion report but was not included or called benign on the initial report is shown in Fig. 3 .
In addition to discrepancies with benignity/malignancy, second-opinion reports detected one case of pneumomediastinum and one case of left vocal cord paralysis that were not mentioned on the outside-hospital report.
Discussion
Given limited personnel and resources, determining whether there is value to second-opinion reviews of 18 F-FDG PET/CT examinations is an important issue. In this study, we show that second-opinion review of 18 F-FDG PET/CT exams performed at outside institutions resulted in a change in assignment of malignancy/ benignity in 31 (13%) of 240 of cases. When a case had a discrepancy, a definite diagnosis was available for 28 (90%) of 31 cases. In the 28 cases where a definitive diagnosis was available, the second-opinion review was correct in 25 (89%) of them. These results suggest that subspecialist review of PET/CT examinations performed at an outside institution increases the accuracy of exam interpretation.
The most common discrepancies were common physiologic and inflammatory sources of 18 F-FDG avidity being described as suspicious/malignant and overlooked lung nodules. It is important to recognize 18 F-FDG-avid A 48-year-old woman with invasive ductal breast cancer. F-FDGavid foci localize symmetrically to the mediastinum and bilateral hila (arrows), without corresponding masses on CT. These findings were called nodal metastases on the initial report. Second-opinion report called these findings likely benign, noting that bilateral hilar and mediastinal nodal metastases without axillary or internal mammary nodal metastases would be highly unlikely. A mediastinal biopsy was performed, yielding a diagnosis of sarcoidosis. CT, computed tomography; 18 F-FDG, fluorine-18 fluorodeoxyglucose.
lesions that are benign, which, in this study, were most commonly benign 18 F-FDG-avid mediastinal lymph nodes from inflammatory etiologies [9] , 18 F-FDG-avid physiologic adnexal cysts in premenopausal women [10] , and physiologic rectal sphincter 18 F-FDG avidity. Not all malignancies will be appreciably 18 F-FDG-avid and may be detected on the CT component of the 18 F-FDG PET/ CT [11, 12] . Lung nodules may be malignant despite an apparent lack of 18 F-FDG avidity [13] . As the field of PET/CT advances and certain findings become more widely recognized, the discrepancies shown by secondopinion reviews may change.
At our institution, not all outside-hospital 18 F-FDG PET/CTs are submitted for formal second-opinion reviews; the referring clinicians determine which studies are submitted for formal reviews. Thus, there is almost certainly selection bias in which studies were submitted for second-opinion reviews. Clinicians may have selected studies for a second opinion if they found that the initial report did not match their clinical impression or if they disagreed with the report findings. This may have increased the proportion of studies for which a second-opinion reader was likely to find a discrepancy.
The finding that second-opinion reads by subspecialists increase the accuracy of interpretations of the submitted exams does not necessarily mean that the subspecialists perform better reads. To show this, initial reads performed by subspecialists would need to be subjected to second-opinion review by nonsubspecialists to determine the proportion of studies where second-opinion review Outside-hospital PET-CT review Ulaner et al. 309
improves upon the subspecialist read. Then, these results would need to be compared with the results of the current study.
A relatively large number of PET/CT reports with unknown primary tumor were reviewed in this study (n = 15 of 240). It may be that our referring clinicians selected these patients as ones for whom they wanted subspecialist review. The only discrepancy noted by subspecialist review of the 15 cases of unknown primary tumor was one case where the subspecialist noted 18 F-FDG-avid stomach wall thickening and suggested work-up. Endoscopy and biopsy showed that this was benign gastritis.
The strengths of this study include the availability of reports for sequential outside-hospital PET/CT examinations, which reduces the potential for selection bias by investigators, as well as the prospective follow-up of patients with discrepancy interpretations to allow for a diagnosis in the vast majority of cases. The limitations of the study include the potential for selection bias in which PET/CT examinations were submitted for second-opinion reviews (as described above), the fact that the second-opinion review was performed at a different time as the initial read and clinical scenario may not have been identical at the two time points, and the single-institution study design, which may limit generalizability.
Subspecialist second-opinion review of PET/CT examinations performed at an outside institution appears to increase the accuracy of exam interpretation. This provides evidence for the value of second-opinion reviews of PET/CT exams, as well as a rationale for the use of limited resources and accommodating the costs associated with performing second-opinion reviews. Larger studies may be needed to confirm these results and determine the tumor types that derive the largest benefit from subspecialist second-opinion reviews.
